fda compounding semaglutide enforcement news november 2025 The announced plans to take action against non-FDA-approved GLP-1 receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new compounded (Wegovy) weight-loss pill from the 🚨 FDA Moves to Permanently

They sit in very different research categories and are not the same type of compound

We dont have a definitive answer yet, but heres what we do know: Using GLP-1s for at least 12 months improves outcomes Stopping often leads to weight regain

Advantages stemming from this medication include: Managed levels of glucose Dampened hunger signals Extended periods of fullness post meals Organic decrease in caloric consumption Positive influences concerning cases concerned with excess body mass

Women should not drop below 1,200 calories daily and men should stay above 1,500

Zepbound and other GLP-1s can cause gastroparesis

Through appetite suppression, increased satiety, and reduced caloric intake, semaglutide aids in achieving sustainable weight loss goals and improving overall metabolic health